|
|
| Product Name: | SAfit2 | | Synonyms: | SAfit2;2-Piperidinecarboxylic acid, 1-[(2S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl]-, (1R)-3-(3,4-dimethoxyphenyl)-1-[3-[2-(4-morpholinyl)ethoxy]phenyl]propyl ester, (2S)-;(R)-3-(3,4-Dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl (S)-1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxylate | | CAS: | 1643125-33-0 | | MF: | C46H62N2O10 | | MW: | 802.99 | | EINECS: | | | Product Categories: | | | Mol File: | 1643125-33-0.mol |  |
| | SAfit2 Chemical Properties |
| Boiling point | 877.0±65.0 °C(Predicted) | | density | 1.168±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 50 mg/ml; DMSO: 50 mg/ml; DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml; Ethanol: 10 mg/ml | | form | A crystalline solid | | pka | 6.43±0.10(Predicted) | | color | Off-white to pink |
| | SAfit2 Usage And Synthesis |
| Description | SAfit2 is a potent inhibitor of FK506-binding protein 51 (FKBP51; Ki = 6 nM). It is highly selective for FKBP51 over FKBP52 (Ki = >50,000 nM) and has increased brain permeability in comparison to SAfit1. SAfit2 (20 mg/kg) enhances HPA axis suppression in mice by decreasing plasma corticosterone levels to a greater extent than in control mice following dexamethasone administration. It also does not increase plasma corticosterone levels as high as in control mice following subsequent administration of corticotropin-releasing factor (CRF; ). It decreases the time spent immobile in the forced swim test and increases the time spent in the open arms of the elevated plus maze, indicating antidepressant-like and anxiolytic-like activity, respectfully. | | Uses | SAFit2 is a highly selective inhibitor of FKBP51. The selective inhibition of FKBP51, using SAFit1(S139583) & SAFit2 , has shown to enhances neurite elongation in neuronal cultures and improves neuroendocrine feedback and stress-coping behavior in mice. |
| | SAfit2 Preparation Products And Raw materials |
|